The Difference Between Blocking PD-1 and PD-L1 in Melanoma
Harriet Kluger, MD, associate professor of medicine (medical oncology), associate director, Hematology/Oncology Fellowship Program, Yale Cancer Center, discusses the difference between blocking PD-1 and PD-L1 in melanoma.
Clinical Pearls
Harriet Kluger, MD, associate professor of medicine (medical oncology), associate director, Hematology/Oncology Fellowship Program, Yale Cancer Center, discusses the difference between blocking PD-1 and PD-L1 in melanoma.
- The complete biology of PD-L1 is not known yet, though there is a theory that blocking it will be less toxic than blocking PD-1
- The toxicity and activity is different in PD-1 and PD-L1
Recent Videos
Related Content
Response Time and BRAF Status Factor Into IO Selection for Melanoma
January 29th 2025Article
During a Case-Based Roundtable® event, Thach-Giao Truong, MD, discussed how data from the CheckMate-067 and RELATIVITY-047 affect their choice of therapy for metastatic melanoma in the first article of a 2-part series.
Read More
